Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Streptoccus Pseudopneumoniae atAssiut UniversityHospitals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03528759
Recruitment Status : Unknown
Verified May 2018 by Zeinab Abdelfadeel, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : May 18, 2018
Last Update Posted : February 5, 2019
Sponsor:
Information provided by (Responsible Party):
Zeinab Abdelfadeel, Assiut University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Streptococcus pseudopneumoniae as suggested by DNA-DNA homology studies is recorded as a species of the Streptococcus mitis/oralis members of viridans group Streptococci; they have some similar features to the Streptococcus mitis/oralis members of viridans Streptococcus pneumoniae

Condition or disease
Pneumonia Streptococcus Infection

Detailed Description:
principle characteristics of Streptococcus. pseudopneumoniae are the lacking of pneumococcal capsule, bile insolubility, the indeterminate sensitivity Or resistance to optochin after incubation in Carbon dioxide (5%), while sensitivity to it after incubation in ambient air Streptococcus . pseudopneumoniae was firstly described in sputum samples of patients with lower respiratory tract infection, particularly those with Chronic Obstructive PulmonaryDiseases pseudopneumoniae is usually misidentified in our laboratories as we usually rely on optochin sensitivity testing with 5% Carbon dioxide detection of Streptococcus. pneumoniae and miss the incubation in ambient air which is the key point for identification of Streptococcus. pseudopneumoniae. Biochemical reactions are usually used to differentiate typical pneumoniae from Streptococc Streptococcus . pseudopneumoniae and other related Streptococci; several molecular techniques have also been used There are several polymerase chain reaction based assays that target specific pneumococcal virulence factors for the typical Streptococc Streptococcus . pneumoniae, such as autolysin A which is the major pneumococcal autolysin and the capsular polysaccharide biosynthesis gene A which is a conservedpneumococcal capsular polysaccharide gene , also aliB-like ORF2 (a gene that usually found in the capsular region of non-capsulated pneumococci; these genetic markers have been used to differentiate S. pneumoniae from other related species.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Streptococcus Pseudopneumoniae as an Emerging Respiratory Tract Pathogen at Assiut University Hospitals
Estimated Study Start Date : July 1, 2019
Estimated Primary Completion Date : August 1, 2019
Estimated Study Completion Date : August 3, 2019
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. identification of Streptococcus. pseudopneumoniae [ Time Frame: 1year ]
    Streptococcus will be identified by polymerase chain Reaction under complete aseptic condition


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Sputum samples will be collected from all studied patients under complete aseptic condition. sputum specimens will be cultivated on 5% sheep blood agar, chocolate agar (Oxoid, UK.
Criteria

Inclusion Criteria:

  • All patients showing signs of respiratory tract infection

Exclusion Criteria:

  • No exclusion criteria
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Zeinab Abdelfadeel, Principle Investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03528759    
Other Study ID Numbers: ZIS
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: February 5, 2019
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Streptococcal Infections
Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses